Leptomeningeal Metastases (LM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032


 Leptomeningeal Metastases (LM) are defined as the spread of the disease to the meninges surrounding the brain and the spinal cord. They are a rare but frequently devastating complication of advanced cancer. When cancer cells are found in your leptomeninges or CSF, this is called leptomeningeal metastases (LM). LM stick onto nerves as they exit your brain and spinal cord, causing weakness and numbness. LM can also clog your leptomeninges and prevent CSF from being drained properly, causing CSF and pressure to build up inside your brain. LC is diagnosed in approximately 5% of patients with advanced cancer. However, it can be detected in up to 20% of cases in autopsy studies. LC is most frequently associated with breast cancer, lung cancer, melanoma, gastrointestinal cancer, and cancer of unknown primary. Also, it can be detected in primary brain tumors and hematologic malignancies. The prognosis of LC is poor, with median survival ranging from 4–6 weeks when untreated to 2–3 months when treated. Current treatment strategies include radiotherapy, systemic antineoplastic agents, and intrathecal chemotherapy.

Thelansis’s “Leptomeningeal Metastases (LM) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Leptomeningeal Metastases (LM) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Leptomeningeal Metastases (LM) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Leptomeningeal Metastases (LM) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Leptomeningeal Metastases (LM) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2021 To 2032

Comments

Popular posts from this blog

Acne Vulgaris – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Herpes Simplex Virus (HSV) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HR+/HER2- Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033